Explore the impact of diversity in clinical trials: improved scientific validity, faster recruitment, regulatory compliance, and stronger commercial outcomes.
Clinical research has traditionally suffered from a lack of diversity, with research focused on a narrow demographic of predominantly white males. Trials have often overlooked how factors like age, sex, race, and ethnicity can have a serious impact on how people respond to treatments. This lack of diversity can skew data, leading to unexpected side effects or reduced effectiveness for groups that weren’t well represented at trial, widening existing inequalities in healthcare.
Expanding the reach of clinical research to include a broader, more inclusive and diverse population helps ensure that medicines work safely and effectively for everyone, taking a meaningful step toward greater health equity.
This article explains the importance of diversity in clinical trials and research, exploring the scientific, operational, regulatory, and commercial benefits of more inclusive medical studies.
What Does Diversity Mean in Clinical Research?
Diversity and inclusion aren't just “nice to haves”; they are essential aspects of performing scientifically sound clinical research, resulting in smoother operations, compliance with regulations, and market success. Diversity encompasses the idea that clinical trial participants represent a range of different groups within wider populations, such as:
- Race and Ethnicity (such as White, Black or African American, Asian, etc.)
- Age (from pediatric to older adults, including those over 65 years of age)
- Sex and Gender (male, female, and gender-diverse populations)
- Socioeconomic Status (including education level, income, employment, etc.)
- Geography (urban vs rural, global representation, etc.)
Who Is Often Underrepresented in Clinical Trials, and Why?
The groups which are often excluded or underrepresented in clinical research vary per study. For example:
Barriers to more diverse clinical trial participation can arise at any stage, from narrow eligibility criteria and trial sites situated in homogeneous communities, to staff lacking language skills or cultural awareness. However, by partnering with a life sciences translator, language and cultural barriers can be overcome with ease.
Mistrust is another major hurdle; just 59% of Black adults in the US trust doctors versus 78% of White adults, and COVID‑19 vaccine hesitancy remains highest among Black and Bangladeshi/Pakistani groups in the UK. In Australia, First Nations patients are more likely to leave the hospital against medical advice than White patients.
Given that clinical trials require an even higher level of trust than regular healthcare interactions, this disparity in trust between doctors and patients becomes even more prominent.
Why Is Diversity Essential for Clinical Research?
There are many benefits to more inclusive studies and trials, for both the researcher and the recipients of the trial’s outcomes. We’ve split these benefits into four categories:
Scientific Benefits
- Enhanced External Validity: Results that generalize more accurately to the real‐world patient population.
- Detection of Subgroup Effects: Ability to identify differences in efficacy or safety across race, age, sex or other factors.
- Improved Risk-Benefit Assessment: More precise understanding of adverse events (side effects) and therapeutic windows (ideal dose range) for all demographic groups.
- Integration of Subgroup-Specific Patterns: This uncovers key effect modifiers and ensures study designs and analyses account for population heterogeneity.
Operational Benefits
- Faster Recruitment: Engaging diverse communities and sites expands the eligible pool, shortening enrollment timelines.
- Better Retention: Culturally-tailored outreach and support build trust, reducing study dropout rates.
- Data Richness: A wider range of patient characteristics creates larger, more informative datasets to improve study outcomes.
- Stronger Community Partnerships: Collaboration with local organizations promotes goodwill and improves study implementation.
Regulatory Benefits
- Alignment with Guidance: Meets FDA and international expectations for inclusive trial populations, increasing approval pathways.
- De‑Risking Future Applications: Early demonstration of safety and efficacy across subgroups reduces the need for post‑marketing commitments.
- Expedited Reviews: Regulators may fast‑track or qualify studies that proactively address diversity, although increasing diversity should never be a “tick box” exercise.
Commercial Benefits
- Broader Market Access: Products tested in diverse populations are approved for – and trusted by – a wider patient base.
- Lower Development Risk: Identifying subgroup risks early avoids costly late‑stage failures or label restrictions.
- Improved ROI: Efficient trials with strong recruitment and retention deliver better value per patient.
- High‑Quality Marketing Data: Robust, representative safety and efficacy data support compelling launches of new drugs.
The Main Challenges of Ensuring Diversity in Clinical Research
As mentioned earlier, many barriers currently reduce or prevent diversity in clinical research. However, by understanding these barriers, we can work towards practical solutions for overcoming them. The challenges of ensuring diversity often include:
Logistical Challenges
- Geographic Barriers: Travel distances and transportation costs can deter potential participants from remote or rural areas.
- Language Needs: Recruiting non-English speakers requires high‑quality translation of protocols, consent forms and study materials; poorly-translated documents can lead to misunderstandings.
- Site Availability: A limited number of trial sites in ethnically-diverse communities restricts access to the study.
Cultural Challenges
- Mistrust of Medical System: Historical lack of inclusivity and perceived bias cause reluctance, especially among marginalized groups.
- Health Literacy Gaps: Complex medical jargon or unfamiliar research processes can confuse participants and hamper informed consent.
- Consent Norms: Cultural differences in decision‑making, such as collective versus individual consent, must be respected and accommodated.
Financial Challenges
- Increased Outreach Costs: While building community partnerships, running local engagement events, and hiring cultural liaisons may appear as added costs upfront, they help reduce recruitment delays and improve participant retention, leading to lower downstream costs and smoother trial execution.
- Translation Expenses: Professional, validated translation services can seem costly, but they prevent miscommunication, reduce protocol deviations, and limit the need for repeated explanations, saving time and resources in the long run.
- Participant Support: Offering support such as childcare or lost-wage reimbursements may increase the study budget, but it significantly lowers dropout rates and improves compliance, resulting in a more complete dataset and fewer costly extensions or re-recruitments.
Scientific / Design Challenges
- Statistical Power for Subgroups: Ensuring enough participants in each demographic group to detect meaningful differences often requires larger sample sizes.
- Complex Stratification: Balancing enrollment quotas across multiple diversity dimensions (race, age, sex, etc.) complicates randomization and analysis plans.
- Heterogeneity Management: Designing protocols and analytical methods that can accommodate and interpret wide variability in responses without inflating false‑positive rates.
What Strategies Can You Implement to Improve Diversity in Clinical Research
To build truly representative trials, researchers must include diversity at every stage, wherever possible. Here are some key strategies:
Diversity-By-Design
- Inclusive Eligibility Criteria: Avoid unnecessary exclusions, such as upper age limits, that disproportionately exclude certain groups.
- Adaptive Enrollment Targets: Set and monitor quotas for race, ethnicity, age, sex and other dimensions, adjusting recruitment efforts to meet diversity goals.
Community Engagement
- Patient Advisory Boards: Involve representatives from underrepresented groups to advise on protocol design, materials and outreach.
- Local Liaisons and Champions: If possible, engage community health workers or cultural ambassadors who understand local languages and norms.
- Mobile Units and Pop‑Up Clinics: Bring trials to community centers, churches, or other accessible public facilities to reduce travel barriers and increase visibility.
Decentralized and Hybrid Models
- Home Visits and Local Labs: Conduct sample collection or drug administration at participants’ homes or nearby facilities.
- Digital Consent and e‑Visits: Use electronic consent platforms and remote monitoring devices to simplify participation for those with mobility, time, or geographic constraints.
Diverse Recruitment for Clinical Research
Recruiting a representative cohort starts at study conception – early engagement ensures that trials meet real‑world needs from the very beginning. Key steps include:
- Strategic Site Selection: Work alongside clinics and health centers serving diverse communities to access broader patient pools.
- Targeted Outreach Campaigns: Involve culturally-tailored messaging via trusted local channels, such as faith groups, community events, and social media, to raise trial awareness.
- Inclusive Consent Processes: Offer materials in multiple languages and formats, and provide assistance to demystify research participation concerns.
- Ongoing Monitoring: Track enrollment metrics against established diversity benchmarks, and use outreach tactics when diversity gaps come to light.
By making diverse recruitment a priority early on, and continuously measuring progress, you lay the foundation for trials that are scientifically robust, operationally efficient, and aligned with both community needs and the expectations of medical regulators.
How Translation Services Increase Diversity in Clinical Trials
Translating clinical materials widens participation in trials by breaking down the language barrier that often excludes non-English speakers. When trial materials (e.g. consent forms and digital interfaces) are accurately translated into the native language of participants, each gains a clearer understanding of the trial’s objectives, procedures, or risks. This clarity not only supports informed consent but also builds confidence that their rights and well-being are being respected.
Incorporating translation also enables teams to design protocols and outreach campaigns that resonate culturally as well as linguistically. This creates a stronger platform for cultural adaptation, ensuring that health beliefs are honored. This nuanced approach also reduces misunderstandings that could lead to non-compliance or early drop-out; thus increasing retention rates among underrepresented groups, and generating stronger safety and efficacy data.
Get in Touch to Discuss Clinical Trial Translation
If you’re looking to broaden the diversity of your clinical research, translation is a significant part of ensuring your study is culturally accepted and properly understood. At Conversis, we work with expert, in-country linguists and custom AI solutions to ensure materials engage local communities and help push trials forward.
For more information on this service or to discuss how we can help, please get in contact, and we will be happy to help!
get in touch
